InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Explore the full record of transactions filed by Albers Jeffrey W., Chairman & CEO. Director active across 1 companies, notably Blueprint Medicines Corp. In total, 14 filings have been published. Total volume traded: €426k. The latest transaction was disclosed on 16 May 2022 — Levée d'options. Regulator: SEC (Form 4). All data is free.
Declarations14 total
€17,91410,000 shares@ €1.79142.3% of flow
Common Stock
SEC:0001415889-22-005222:0·
€68,8645,000 shares@ €13.77299.0% of flow
Common Stock
SEC:0001415889-22-003957:0·
€426,4827,862 shares@ €54.24655.7% of flow
Common Stock
SEC:0001415889-22-002740:0·
07,500 shares0
Common Stock
SEC:0001415889-22-002431:0·
€12,2587,500 shares@ €1.63449.7% of flow
Common Stock
SEC:0001179110-21-010218·
€12,2587,500 shares@ €1.63441.6% of flow
Common Stock
SEC:0001179110-21-010218:0·
€64,9415,000 shares@ €12.988251.4% of flow
Common Stock
SEC:0001179110-21-009819·
€64,9415,000 shares@ €12.98828.5% of flow
Common Stock
SEC:0001179110-21-009819:0·
€25,45016,000 shares@ €1.590620.2% of flow
Common Stock
SEC:0001179110-21-008474·
€25,45016,000 shares@ €1.59063.3% of flow
Common Stock
SEC:0001179110-21-008474:0·
€12,0117,500 shares@ €1.60159.5% of flow
Common Stock
SEC:0001179110-21-008347·
€12,0117,500 shares@ €1.60151.6% of flow
Common Stock
SEC:0001179110-21-008347:0·
€11,6127,500 shares@ €1.54829.2% of flow
Common Stock
SEC:0001179110-21-005387·
€11,6127,500 shares@ €1.54821.5% of flow
Common Stock
SEC:0001179110-21-005387:0·
14 of 14 declarations
About Albers Jeffrey W.
Jeffrey W. Albers is the CEO and President at Blueprint Medicines Corp. He leads the company with a strategic vision focused on innovation in the biopharmaceutical sector. Albers is responsible for implementing growth and product development strategies. His leadership is essential for positioning Blueprint Medicines as a key player in the field of precision medicine.
